FDA Approves Revumenib for High-Risk Acute Leukemia

418 Views

Emedinexus 10 April 2025

The FDA has approved revumenib (Revuforj) for treating relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. This menin inhibitor, developed by Syndax Pharmaceuticals, offers a targeted therapy option for this high-risk leukemia subtype.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.